Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kontafarma China HoldingsHKSE:01312 +3.13% EV-to-FCF is 4.50 as of Aug. 28, 2026. The stock has 5 warning signs investors should review. Among 559 Drug Manufacturers companies, Kontafarma China Holdings ranks better than 92.49% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kontafarma China Holdings's Enterprise Value is HK$239.4 Mil.
Kontafarma China Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$53.2 Mil. Therefore, Kontafarma China Holdings's EV-to-FCF for today is 4.50.
The historical rank and industry rank for Kontafarma China Holdings's EV-to-FCF or its related term are showing as below:
HKSE:01312'
s EV-to-FCF Range Over the Past 10 Years
Min: -134.29 Med: -18.37 Max: 46.59
Current: 4.61
During the past 13 years, the highest EV-to-FCF of Kontafarma China Holdings was 46.59. The lowest was -134.29. And the median was -18.37.
HKSE:01312's EV-to-FCF is ranked better than 92.49% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.58
vs HKSE:01312: 4.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kontafarma China Holdings (HKSE:01312) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kontafarma China Holdings's PE Ratio (TTM) for today is calculated as:
Kontafarma China Holdings's share price for today is HK$0.033.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kontafarma China Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.077.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kontafarma China Holdings EV-to-FCF Related Terms
Kontafarma China Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontafarma China Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kontafarma China Holdings's EV-to-FCF falls into.
Kontafarma China Holdings's current Enterprise Value is HK$239.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kontafarma China Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$53.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontafarma China Holdings (HKSE:01312) has a EV-to-FCF of 4.50 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kontafarma China Holdings and its competitors. According to the industry distribution chart, Kontafarma China Holdings ranks #42 out of 559 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is Kontafarma China Holdings' EV-to-FCF too high?
Kontafarma China Holdings' current EV-to-FCF is 4.50. The Drug Manufacturers industry median EV-to-FCF is 20.58. Kontafarma China Holdings' value of 4.50 is 78.1% below this industry median. Based on the distribution chart, Kontafarma China Holdings ranks #42 out of 559 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Kontafarma China Holdings' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kontafarma China Holdings ranks #42 out of 559 companies for EV-to-FCF. This places Kontafarma China Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.58. Kontafarma China Holdings' value of 4.50 is 78.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.58, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kontafarma China Holdings's current EV-to-FCF of 4.50 is 78.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kontafarma China Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kontafarma China Holdings's current EV-to-FCF is 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 17.5% below its estimated fair value. The current EV-to-FCF is 4.50 and 78.1% below the Drug Manufacturers industry median of 20.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current EV-to-FCF is 4.50 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01312 has been successfully added to your 
